Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

Completed

• Conditions: Gram-Positive Bacterial Infections; Escherichia Coli Infections; Klebsiella Infections

• Registration Number: NCT00167999
• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary

To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units

Detailed Description

Not available

Study Timeline

• Study Start: 2005-02
• Study First Submitted: 2005-09-11
• Study First Submitted QC: 2005-09-11
• Study First Posted: 2005-09-14
• Status Verified: 2007-03
• Last Update Submitted: 2007-03-14
• Last Update Posted: 2007-03-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• Eligible patients of either sex, 15 years of age or older
• Patients who are admitted to the department of hematology and oncology
• Provide written informed consent

Exclusion Criteria

• Patients who have hypersensitivity to β-lactam antibiotics
• Female who are pregnant or breast-feeding
• Any underlying conditions or non-infectious diseases that will be ultimately fatal within 30 days

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified